Gedeon Richter Launches Terrosa (biosimilar- teriparatide) in Europe

Share this
Gedeon Richter Launches Terrosa (biosimilar- teriparatide) in Europe

Gedeon Richter Launches Terrosa (biosimilar- teriparatide) in Europe


  • Richter has launched Terrosa- a biosimilar to Eli Lilly’s Forsteo approved for osteoporosis in postmenopausal women and in men at high risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture
  • Richter launched Terrosa through its affiliates in Europe following the patent expiry of the Forsteo in Aug’ 2019. The in vivo non-clinical studies and the clinical study demonstrated biosimilarity data to Forsteo
  • Terrosa is a biosimilar to the biologically active fragment of the human parathyroid hormone which replaces the natural hormone thus stimulating bone formation and has received EC’s approval in Jan’2017 following CHMP’s positive opinion

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Business Review

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions